DSIP (Delta Sleep-Inducing Peptide) — Peptides

Overview

Delta Sleep-Inducing Peptide (DSIP) is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from rabbit cerebral venous blood during electrically induced slow-wave sleep in 1977 by Schoenenberger and Monnier. DSIP gained its name from its ability to induce delta-wave (slow-wave) sleep in recipient rabbits when administered intravenously. Despite decades of research, DSIP's mechanism of action remains incompletely understood. It appears to modulate sleep-wake cycles through interactions with GABAergic, glutamatergic, and opioid neurotransmitter systems, as well as influencing cortisol rhythms and stress response. Human clinical studies are limited but suggest that DSIP may improve sleep quality, reduce sleep latency, and normalize disrupted circadian patterns in insomnia patients. Small studies in chronic insomnia showed improved subjective sleep quality and increased delta-wave activity on EEG. DSIP also shows analgesic properties and has been studied for narcolepsy, alcohol withdrawal, and stress-related conditions. However, DSIP presents significant pharmacological challenges: it has a very short plasma half-life (approximately 7-8 minutes), is rapidly degraded by aminopeptidases, and requires IV or subcutaneous administration. No controlled, large-scale clinical trials have been conducted, and DSIP has never received regulatory approval for any indication. It remains a research compound of historical interest in sleep medicine.

Indications

• Investigational: Chronic insomnia and sleep disorders
• Investigational: Circadian rhythm normalization
• Investigational: Narcolepsy (historical studies)
• Research only: Stress modulation and pain management

Mechanism of Action

DSIP promotes slow-wave (delta) sleep stages, increasing restorative deep sleep and sleep efficiency

Dosing

Evidence Grade

GRADE D

Safety & Contraindications

• Very limited human safety data
• Extremely short half-life (~7-8 minutes) — challenging to administer effectively
• No standardized pharmaceutical preparation available
• Research peptide only — quality varies
• Some reports of paradoxical alertness at certain doses
• Not FDA-approved for any indication